Last reviewed · How we verify

NCT05245695

Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)

Recruiting now Last updated 25 June 2025
What this trial tests

trial testing Observational study, no intervention in Endometriosis in 1,200 participants. Currently enrolling.

Timeline
12 July 2022
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorAspira Women's Health
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,200
Start date12 July 2022
Primary completion30 June 2026
Estimated completion30 June 2026
Sites10 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Aspira Women's Health

Who can join

Adults 14 to 50, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observational study, no intervention

Trials testing the same drug.

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other Aspira Women's Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05245695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing